Pravastatin

Pravastatin

SCHEMBL6317379

CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)[O-])[C@H]21.[Li+]

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

HMGCR

The experimentally established mechanism targets of Pravastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
HMGCR known ✓ P04035 10/20 0.97
ALOX15 P16050 1/20 0.97
SLCO1B1 Q9Y6L6 3/20 0.84
SLC22A8 Q8TCC7 1/20 0.84
SLCO1B3 Q9NPD5 1/20 0.84
HDAC1 Q13547 2/20 0.69
HDAC2 Q92769 2/20 0.69
HDAC6 Q9UBN7 2/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pravastatin SCHEMBL2225672 0.98 HMGCR (0.97) HMGCRALOX15SLCO1B1SLC22A8SLCO1B3
Pravastatin SCHEMBL899410 0.98 HMGCR (0.97) HMGCRALOX15SLCO1B1SLC22A8SLCO1B3
Pravastatin SCHEMBL2817795 0.98 HMGCR (0.97) HMGCRALOX15SLCO1B1SLC22A8SLCO1B3
Pravastatin SCHEMBL3013 0.98 HMGCR (1.00) HMGCRALOX15SLCO1B1SLC22A8SLCO1B3
Pravastatin SCHEMBL25969 0.98 HMGCR (0.97) HMGCRALOX15SLCO1B1SLC22A8SLCO1B3
Pravastatin SCHEMBL3014 0.98 HMGCR (1.00) HMGCRALOX15SLCO1B1SLC22A8SLCO1B3
Pravastatin SCHEMBL5598406 0.98 HMGCR (1.00) HMGCRALOX15SLCO1B1SLC22A8SLCO1B3
Pravastatin SCHEMBL27522597 0.98 HMGCR (1.00) HMGCRALOX15SLCO1B1SLC22A8SLCO1B3
Pravastatin SCHEMBL14472019 0.98 HMGCR (1.00) HMGCRALOX15SLCO1B1SLC22A8SLCO1B3
Pravastatin SCHEMBL2175991 0.97 HMGCR (0.98) HMGCRALOX15SLCO1B1SLC22A8SLCO1B3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050004235-A1 Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease CARDAX PHARMACEUTICALS, INC. 2005-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004235-A1 Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease GYS2, HCCS, CPT1A HMGCR 21/4885ALOX15 51/4885SLCO1B1 1661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.